Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zachariah DeFilipp

Showing results (111-120 of 141) with videos related to

Pageof 15
Sort By:
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 28, 2018
Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow TransplantationYoshihiro Inamoto, Nuria Valdés-Sanz, Yoko Ogawa, et al.
Cancer|November 11, 2017
Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphomaRegina M Myers, Brian T Hill, Bronwen E Shaw, et al.
Blood Advances|August 15, 2025
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHDYu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Blood Advances|December 10, 2019
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host diseaseHrishikesh K Srinagesh, Umut Özbek, Urvi Kapoor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 18, 2016
Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMTZachariah DeFilipp, Rafael F Duarte, John A Snowden, et al.
Blood Advances|November 7, 2018
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemiaSaurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Blood Advances|March 14, 2020
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemiaCatherine J Lee, Soyoung Kim, Heather R Tecca, et al.
Bone Marrow Transplantation|January 19, 2018
Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMTDavid Buchbinder, Debra Lynch Kelly, Rafael F Duarte, et al.
Pageof 15

Showing results (111-120 of 141) with videos related to

Sort By:
Pageof 15
Blood Advances|June 14, 2023
Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHDYu Akahoshi, Nikolaos Spyrou, William J Hogan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 28, 2018
Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow TransplantationYoshihiro Inamoto, Nuria Valdés-Sanz, Yoko Ogawa, et al.
Cancer|November 11, 2017
Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphomaRegina M Myers, Brian T Hill, Bronwen E Shaw, et al.
Blood Advances|August 15, 2025
The MAGIC Composite Response: A Novel Endpoint Integrating Clinical and Biomarker Parameters for Acute GVHDYu Akahoshi, Joseph Portelli, Nikolaos Katsivelos, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Blood Advances|December 10, 2019
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host diseaseHrishikesh K Srinagesh, Umut Özbek, Urvi Kapoor, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 18, 2016
Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMTZachariah DeFilipp, Rafael F Duarte, John A Snowden, et al.
Blood Advances|November 7, 2018
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemiaSaurabh Chhabra, Kwang Woo Ahn, Zhen-Huan Hu, et al.
Blood Advances|March 14, 2020
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemiaCatherine J Lee, Soyoung Kim, Heather R Tecca, et al.
Bone Marrow Transplantation|January 19, 2018
Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMTDavid Buchbinder, Debra Lynch Kelly, Rafael F Duarte, et al.
Pageof 15